Health Canada Has Issued A Notice Of Compliance For Sanofi/Regeneron Dupixent (Dupilumab Injection) For The Treatment Of Patients Aged 1 Year And Older, Weighing At Least 15 Kg, With Eosinophilic Esophagitis
Health Canada Has Issued A Notice Of Compliance For Sanofi/Regeneron Dupixent (Dupilumab Injection) For The Treatment Of Patients Aged 1 Year And Older, Weighing At Least 15 Kg, With Eosinophilic Esophagitis
賽諾菲安萬特/再生元的Dupixent（杜比盧瑪注射液）已獲得加拿大衛生部的合規通知，用於治療年齡在1歲及以上，體重至少15公斤的嗜酸性食道炎患者。
This approval expands the initial Health Canada Notice of Compliance for eosinophilic esophagitis in May 2023 for patients aged 12 years and older, weighing at least 40 kg.
該批准擴大了2023年5月加拿大衛生部最初的嗜酸性食管炎合規通知，適用於年齡在12歲及以上、體重至少爲40千克的患者。
譯文內容由第三人軟體翻譯。
以上內容僅用作資訊或教育之目的，不構成與富途相關的任何投資建議。富途竭力但無法保證上述全部內容的真實性、準確性和原創性。